Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Early Detection of Cancer | 17 | 2023 | 1338 | 2.770 |
Why?
|
Breast Neoplasms | 65 | 2024 | 16183 | 2.630 |
Why?
|
Mass Screening | 12 | 2024 | 1545 | 2.510 |
Why?
|
Selective Estrogen Receptor Modulators | 10 | 2018 | 128 | 1.990 |
Why?
|
Mammography | 18 | 2024 | 1052 | 1.510 |
Why?
|
Raloxifene Hydrochloride | 8 | 2015 | 46 | 1.210 |
Why?
|
Aromatase Inhibitors | 4 | 2022 | 311 | 1.200 |
Why?
|
Risk Reduction Behavior | 5 | 2017 | 209 | 1.140 |
Why?
|
Carcinoma, Lobular | 5 | 2023 | 616 | 0.870 |
Why?
|
Uterine Cervical Dysplasia | 4 | 2023 | 209 | 0.860 |
Why?
|
Patient Participation | 6 | 2020 | 453 | 0.830 |
Why?
|
Tamoxifen | 12 | 2022 | 875 | 0.810 |
Why?
|
Hyperplasia | 7 | 2023 | 557 | 0.810 |
Why?
|
Medical Oncology | 3 | 2023 | 1463 | 0.800 |
Why?
|
Breast Carcinoma In Situ | 2 | 2020 | 17 | 0.780 |
Why?
|
Breast Self-Examination | 2 | 2012 | 17 | 0.770 |
Why?
|
Breast | 8 | 2021 | 1366 | 0.750 |
Why?
|
Decision Making | 7 | 2018 | 1249 | 0.680 |
Why?
|
Precancerous Conditions | 4 | 2023 | 1033 | 0.660 |
Why?
|
Smokers | 1 | 2020 | 154 | 0.630 |
Why?
|
Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 11 | 0.580 |
Why?
|
Decision Support Techniques | 3 | 2020 | 601 | 0.540 |
Why?
|
Exercise | 4 | 2021 | 1206 | 0.540 |
Why?
|
Female | 80 | 2024 | 148486 | 0.530 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2022 | 1231 | 0.510 |
Why?
|
Risk Assessment | 15 | 2024 | 6752 | 0.500 |
Why?
|
Papillomavirus Infections | 3 | 2023 | 999 | 0.500 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2023 | 1900 | 0.480 |
Why?
|
Carcinoma in Situ | 2 | 2015 | 488 | 0.470 |
Why?
|
Middle Aged | 55 | 2024 | 90030 | 0.450 |
Why?
|
Patient-Centered Care | 1 | 2016 | 318 | 0.440 |
Why?
|
Awareness | 2 | 2012 | 114 | 0.430 |
Why?
|
Breast Density | 3 | 2024 | 20 | 0.420 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 7779 | 0.420 |
Why?
|
Insurance Coverage | 1 | 2014 | 274 | 0.400 |
Why?
|
Humans | 83 | 2024 | 270033 | 0.390 |
Why?
|
Practice Guidelines as Topic | 4 | 2019 | 2388 | 0.380 |
Why?
|
Lung Neoplasms | 4 | 2020 | 12019 | 0.360 |
Why?
|
High-Intensity Interval Training | 2 | 2021 | 10 | 0.360 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 4 | 2023 | 690 | 0.360 |
Why?
|
Breast Diseases | 3 | 2020 | 200 | 0.360 |
Why?
|
Adult | 40 | 2024 | 81689 | 0.340 |
Why?
|
Risk Factors | 21 | 2023 | 17824 | 0.330 |
Why?
|
Medicare | 1 | 2014 | 925 | 0.330 |
Why?
|
Dietary Supplements | 2 | 2024 | 562 | 0.300 |
Why?
|
Vaginal Smears | 4 | 2023 | 166 | 0.280 |
Why?
|
Ultrasonography, Mammary | 6 | 2022 | 387 | 0.280 |
Why?
|
Aged | 35 | 2024 | 73127 | 0.270 |
Why?
|
Age Factors | 6 | 2018 | 5449 | 0.270 |
Why?
|
Overweight | 2 | 2020 | 484 | 0.270 |
Why?
|
Algorithms | 2 | 2016 | 3896 | 0.260 |
Why?
|
Health Literacy | 2 | 2019 | 117 | 0.260 |
Why?
|
Patient Compliance | 3 | 2019 | 676 | 0.250 |
Why?
|
Volatile Organic Compounds | 1 | 2024 | 13 | 0.240 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2019 | 1229 | 0.240 |
Why?
|
Cholecalciferol | 1 | 2024 | 49 | 0.230 |
Why?
|
Breath Tests | 1 | 2024 | 192 | 0.230 |
Why?
|
Counseling | 4 | 2023 | 381 | 0.230 |
Why?
|
Cardiorespiratory Fitness | 2 | 2021 | 20 | 0.230 |
Why?
|
Quality of Life | 2 | 2016 | 4772 | 0.230 |
Why?
|
Perception | 4 | 2022 | 349 | 0.220 |
Why?
|
Neoplasms | 5 | 2019 | 15902 | 0.220 |
Why?
|
Biopsy, Large-Core Needle | 4 | 2023 | 139 | 0.220 |
Why?
|
United States | 7 | 2020 | 15776 | 0.220 |
Why?
|
Catechin | 2 | 2014 | 34 | 0.220 |
Why?
|
Health Promotion | 1 | 2007 | 510 | 0.220 |
Why?
|
Premenopause | 2 | 2024 | 138 | 0.220 |
Why?
|
Family Practice | 1 | 2023 | 131 | 0.210 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2020 | 10382 | 0.210 |
Why?
|
Nipple Discharge | 1 | 2022 | 8 | 0.210 |
Why?
|
Cancer Survivors | 2 | 2020 | 744 | 0.210 |
Why?
|
Anticarcinogenic Agents | 2 | 2001 | 368 | 0.200 |
Why?
|
Societies, Medical | 2 | 2018 | 1318 | 0.200 |
Why?
|
Health Personnel | 3 | 2023 | 649 | 0.200 |
Why?
|
Point-of-Care Systems | 1 | 2024 | 212 | 0.200 |
Why?
|
Medical Overuse | 2 | 2018 | 51 | 0.190 |
Why?
|
Risk | 6 | 2021 | 1937 | 0.190 |
Why?
|
Vitamin D | 2 | 2024 | 261 | 0.190 |
Why?
|
Primary Prevention | 2 | 2015 | 233 | 0.190 |
Why?
|
Mastectomy | 4 | 2022 | 1553 | 0.190 |
Why?
|
Celecoxib | 1 | 2020 | 198 | 0.170 |
Why?
|
Resistance Training | 1 | 2019 | 39 | 0.160 |
Why?
|
Postmenopause | 5 | 2019 | 377 | 0.160 |
Why?
|
Comprehension | 1 | 2019 | 103 | 0.160 |
Why?
|
Papanicolaou Test | 2 | 2017 | 116 | 0.160 |
Why?
|
Device Removal | 1 | 2021 | 338 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2018 | 2646 | 0.160 |
Why?
|
Obesity | 3 | 2020 | 2901 | 0.160 |
Why?
|
Patient Education as Topic | 2 | 2021 | 744 | 0.160 |
Why?
|
Stakeholder Participation | 1 | 2018 | 42 | 0.150 |
Why?
|
CA-125 Antigen | 2 | 2024 | 228 | 0.150 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2020 | 402 | 0.150 |
Why?
|
Health Behavior | 2 | 2015 | 600 | 0.150 |
Why?
|
False Positive Reactions | 1 | 2018 | 372 | 0.150 |
Why?
|
Antineoplastic Agents | 4 | 2015 | 14615 | 0.150 |
Why?
|
Health Communication | 1 | 2018 | 36 | 0.150 |
Why?
|
Atypical Squamous Cells of the Cervix | 1 | 2017 | 3 | 0.150 |
Why?
|
Health Plan Implementation | 1 | 2018 | 83 | 0.150 |
Why?
|
Human Papillomavirus DNA Tests | 1 | 2017 | 16 | 0.150 |
Why?
|
Incidence | 7 | 2018 | 5806 | 0.140 |
Why?
|
Ultrasonography | 4 | 2024 | 1928 | 0.140 |
Why?
|
Receptors, Estrogen | 4 | 2016 | 2158 | 0.140 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2018 | 166 | 0.140 |
Why?
|
Professional-Patient Relations | 1 | 2017 | 114 | 0.140 |
Why?
|
Genital Neoplasms, Female | 1 | 2023 | 788 | 0.140 |
Why?
|
Motivation | 1 | 2020 | 516 | 0.140 |
Why?
|
Endometrial Neoplasms | 3 | 2024 | 1388 | 0.140 |
Why?
|
Breast Implants | 1 | 2021 | 375 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 7892 | 0.130 |
Why?
|
Patient Preference | 1 | 2018 | 228 | 0.130 |
Why?
|
Feasibility Studies | 3 | 2020 | 2358 | 0.130 |
Why?
|
Logistic Models | 7 | 2021 | 3438 | 0.130 |
Why?
|
Follow-Up Studies | 6 | 2019 | 15172 | 0.130 |
Why?
|
Program Evaluation | 1 | 2018 | 601 | 0.120 |
Why?
|
Biomarkers | 2 | 2019 | 5046 | 0.120 |
Why?
|
Information Dissemination | 1 | 2018 | 266 | 0.120 |
Why?
|
Aged, 80 and over | 8 | 2020 | 30923 | 0.120 |
Why?
|
Clinical Decision-Making | 1 | 2018 | 530 | 0.120 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 165 | 0.120 |
Why?
|
Health Education | 1 | 2017 | 303 | 0.120 |
Why?
|
Retrospective Studies | 12 | 2023 | 39736 | 0.120 |
Why?
|
Surveys and Questionnaires | 5 | 2020 | 5906 | 0.120 |
Why?
|
Biopsy | 3 | 2018 | 3384 | 0.120 |
Why?
|
North America | 1 | 2015 | 337 | 0.120 |
Why?
|
Androstadienes | 1 | 2015 | 172 | 0.120 |
Why?
|
Tea | 1 | 2014 | 46 | 0.120 |
Why?
|
Computer Simulation | 1 | 2019 | 1570 | 0.120 |
Why?
|
Erotica | 1 | 2013 | 11 | 0.120 |
Why?
|
Internet | 2 | 2017 | 689 | 0.110 |
Why?
|
Mammaplasty | 1 | 2021 | 714 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 3 | 2018 | 5773 | 0.110 |
Why?
|
Cognition | 2 | 2010 | 968 | 0.110 |
Why?
|
Libido | 1 | 2013 | 37 | 0.110 |
Why?
|
Papilloma | 1 | 2013 | 86 | 0.110 |
Why?
|
Patient Care Team | 2 | 2016 | 822 | 0.110 |
Why?
|
Activities of Daily Living | 1 | 2016 | 553 | 0.110 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 1032 | 0.110 |
Why?
|
Ovarian Neoplasms | 2 | 2024 | 4785 | 0.110 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2017 | 440 | 0.110 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2013 | 71 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 599 | 0.110 |
Why?
|
Human papillomavirus 18 | 1 | 2012 | 42 | 0.110 |
Why?
|
Russia | 1 | 2012 | 55 | 0.100 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 4944 | 0.100 |
Why?
|
Receptors, Progesterone | 2 | 2016 | 1603 | 0.100 |
Why?
|
Neoplasm Grading | 1 | 2017 | 1821 | 0.100 |
Why?
|
Biopsy, Fine-Needle | 2 | 2020 | 687 | 0.100 |
Why?
|
Biomarkers, Tumor | 6 | 2024 | 10695 | 0.100 |
Why?
|
Video Recording | 1 | 2014 | 278 | 0.100 |
Why?
|
Plant Extracts | 1 | 2014 | 225 | 0.100 |
Why?
|
Vaginal Neoplasms | 1 | 2012 | 152 | 0.100 |
Why?
|
Life Style | 1 | 2015 | 617 | 0.100 |
Why?
|
Biopsy, Needle | 2 | 2012 | 1376 | 0.090 |
Why?
|
India | 1 | 2012 | 312 | 0.090 |
Why?
|
Human papillomavirus 16 | 1 | 2012 | 255 | 0.090 |
Why?
|
China | 1 | 2012 | 634 | 0.090 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2014 | 657 | 0.090 |
Why?
|
Triazoles | 1 | 2015 | 628 | 0.090 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2016 | 530 | 0.090 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2010 | 34 | 0.090 |
Why?
|
Nitriles | 1 | 2015 | 938 | 0.090 |
Why?
|
Minority Health | 1 | 2009 | 16 | 0.090 |
Why?
|
Databases, Factual | 1 | 2017 | 2231 | 0.090 |
Why?
|
Radiography | 1 | 2014 | 1984 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2020 | 156 | 0.080 |
Why?
|
Radiation Dosage | 1 | 2014 | 1042 | 0.080 |
Why?
|
Male | 9 | 2020 | 127917 | 0.080 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2010 | 347 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1387 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2005 | 841 | 0.080 |
Why?
|
Nomograms | 1 | 2010 | 312 | 0.080 |
Why?
|
Prognosis | 6 | 2019 | 22451 | 0.080 |
Why?
|
Pilot Projects | 3 | 2020 | 2843 | 0.070 |
Why?
|
Decision Trees | 1 | 2007 | 181 | 0.070 |
Why?
|
Double-Blind Method | 4 | 2019 | 2586 | 0.070 |
Why?
|
Image-Guided Biopsy | 2 | 2023 | 336 | 0.070 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2020 | 629 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 3653 | 0.070 |
Why?
|
Attitude to Health | 1 | 2009 | 434 | 0.070 |
Why?
|
Practice Patterns, Physicians' | 1 | 2015 | 1299 | 0.070 |
Why?
|
Genetic Testing | 1 | 2015 | 1695 | 0.070 |
Why?
|
Time Factors | 2 | 2018 | 12953 | 0.070 |
Why?
|
Estrogens | 1 | 2010 | 808 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2021 | 5666 | 0.060 |
Why?
|
Alphapapillomavirus | 1 | 2007 | 172 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2020 | 33691 | 0.060 |
Why?
|
Estrogen Receptor Modulators | 1 | 2005 | 110 | 0.060 |
Why?
|
Survivors | 2 | 2013 | 1022 | 0.060 |
Why?
|
Smoking | 1 | 2014 | 2548 | 0.060 |
Why?
|
Body Weight | 2 | 2020 | 1306 | 0.060 |
Why?
|
Psychometrics | 1 | 2009 | 969 | 0.060 |
Why?
|
Brain | 2 | 2018 | 4210 | 0.060 |
Why?
|
Case-Control Studies | 5 | 2017 | 6204 | 0.060 |
Why?
|
Thyroid Hormones | 1 | 2005 | 111 | 0.060 |
Why?
|
Qualitative Research | 2 | 2018 | 635 | 0.060 |
Why?
|
Lysophospholipids | 1 | 2004 | 148 | 0.060 |
Why?
|
Odds Ratio | 3 | 2017 | 2296 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2005 | 313 | 0.050 |
Why?
|
Hypothyroidism | 1 | 2005 | 207 | 0.050 |
Why?
|
Prospective Studies | 6 | 2020 | 13378 | 0.050 |
Why?
|
Premedication | 1 | 2002 | 133 | 0.050 |
Why?
|
Dissent and Disputes | 1 | 2022 | 40 | 0.050 |
Why?
|
Ki-67 Antigen | 2 | 2020 | 675 | 0.050 |
Why?
|
Medical Device Recalls | 1 | 2021 | 5 | 0.050 |
Why?
|
Models, Statistical | 1 | 2007 | 1185 | 0.050 |
Why?
|
Silicone Gels | 1 | 2021 | 19 | 0.050 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 294 | 0.050 |
Why?
|
Surface Properties | 1 | 2021 | 188 | 0.050 |
Why?
|
Adaptation, Psychological | 1 | 2005 | 787 | 0.050 |
Why?
|
Carcinoma | 1 | 2012 | 2607 | 0.050 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2020 | 30 | 0.050 |
Why?
|
Equipment Failure | 1 | 2021 | 191 | 0.040 |
Why?
|
Papillomaviridae | 1 | 2023 | 636 | 0.040 |
Why?
|
Texas | 3 | 2019 | 6430 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2007 | 3210 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2022 | 379 | 0.040 |
Why?
|
Neoplasm Staging | 5 | 2016 | 13996 | 0.040 |
Why?
|
Body Mass Index | 2 | 2019 | 2238 | 0.040 |
Why?
|
Histones | 1 | 2007 | 1512 | 0.040 |
Why?
|
Audiovisual Aids | 1 | 2019 | 39 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2020 | 118 | 0.040 |
Why?
|
DNA Damage | 1 | 2007 | 1981 | 0.040 |
Why?
|
Truth Disclosure | 1 | 2021 | 178 | 0.040 |
Why?
|
Triage | 1 | 2021 | 256 | 0.040 |
Why?
|
Radiotherapy | 1 | 2006 | 1858 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2022 | 525 | 0.040 |
Why?
|
Genetic Variation | 1 | 2007 | 2165 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 5061 | 0.040 |
Why?
|
Prosthesis Design | 1 | 2021 | 653 | 0.040 |
Why?
|
Breast Implantation | 1 | 2021 | 222 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2012 | 748 | 0.040 |
Why?
|
Pamphlets | 1 | 2018 | 34 | 0.040 |
Why?
|
Exercise Therapy | 1 | 2021 | 293 | 0.040 |
Why?
|
Tretinoin | 1 | 2000 | 618 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 103 | 0.040 |
Why?
|
Life Expectancy | 1 | 2018 | 129 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 5153 | 0.040 |
Why?
|
Organs at Risk | 1 | 2020 | 558 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2006 | 9040 | 0.040 |
Why?
|
Whole Body Imaging | 1 | 2018 | 120 | 0.040 |
Why?
|
Culture | 1 | 2017 | 104 | 0.040 |
Why?
|
Thromboembolism | 2 | 2010 | 150 | 0.040 |
Why?
|
Patient Outcome Assessment | 1 | 2018 | 245 | 0.030 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 389 | 0.030 |
Why?
|
Observation | 1 | 2016 | 52 | 0.030 |
Why?
|
Trust | 1 | 2017 | 109 | 0.030 |
Why?
|
Anxiety | 1 | 2023 | 1236 | 0.030 |
Why?
|
Probability | 2 | 2010 | 883 | 0.030 |
Why?
|
Cataract | 2 | 2010 | 236 | 0.030 |
Why?
|
Neuropsychological Tests | 2 | 2010 | 1145 | 0.030 |
Why?
|
Disease Management | 1 | 2021 | 1087 | 0.030 |
Why?
|
Blood Glucose | 1 | 2020 | 1260 | 0.030 |
Why?
|
Informed Consent | 1 | 2018 | 416 | 0.030 |
Why?
|
Heterozygote | 1 | 2018 | 1055 | 0.030 |
Why?
|
Myocardial Ischemia | 2 | 2010 | 400 | 0.030 |
Why?
|
Health Status | 1 | 2018 | 630 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2006 | 10258 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2002 | 3993 | 0.030 |
Why?
|
Breast Feeding | 1 | 2016 | 246 | 0.030 |
Why?
|
Forecasting | 1 | 2016 | 699 | 0.030 |
Why?
|
Adenocarcinoma | 2 | 2010 | 7883 | 0.030 |
Why?
|
Registries | 2 | 2016 | 2205 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 155 | 0.030 |
Why?
|
Arousal | 1 | 2013 | 128 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2012 | 4043 | 0.030 |
Why?
|
Placebos | 1 | 2014 | 443 | 0.030 |
Why?
|
Fractures, Bone | 2 | 2006 | 310 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1101 | 0.030 |
Why?
|
Photomicrography | 1 | 2012 | 23 | 0.030 |
Why?
|
Triglycerides | 1 | 2014 | 610 | 0.020 |
Why?
|
Patient Safety | 1 | 2016 | 612 | 0.020 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2012 | 106 | 0.020 |
Why?
|
Cholesterol | 1 | 2014 | 658 | 0.020 |
Why?
|
Receptor, ErbB-2 | 2 | 2016 | 2650 | 0.020 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2010 | 40 | 0.020 |
Why?
|
Emotions | 1 | 2013 | 560 | 0.020 |
Why?
|
Radiography, Interventional | 1 | 2012 | 311 | 0.020 |
Why?
|
Fractures, Spontaneous | 1 | 2010 | 87 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2009 | 224 | 0.020 |
Why?
|
Drug Utilization | 1 | 2010 | 188 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2012 | 1320 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2012 | 424 | 0.020 |
Why?
|
Area Under Curve | 1 | 2010 | 729 | 0.020 |
Why?
|
Models, Psychological | 1 | 2009 | 178 | 0.020 |
Why?
|
Women's Health | 1 | 2009 | 197 | 0.020 |
Why?
|
Young Adult | 2 | 2018 | 22134 | 0.020 |
Why?
|
DNA Probes, HPV | 1 | 2007 | 12 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2007 | 66 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2014 | 1577 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 4819 | 0.020 |
Why?
|
Research Design | 2 | 2005 | 1569 | 0.020 |
Why?
|
Patient Selection | 2 | 2005 | 2026 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2005 | 107 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2007 | 1039 | 0.020 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2016 | 1391 | 0.020 |
Why?
|
Thyroid Function Tests | 1 | 2005 | 38 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 1309 | 0.020 |
Why?
|
DNA, Viral | 1 | 2007 | 753 | 0.020 |
Why?
|
Uterus | 1 | 2010 | 798 | 0.020 |
Why?
|
Bias | 1 | 2005 | 214 | 0.020 |
Why?
|
Thyroxine | 1 | 2005 | 114 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2018 | 8668 | 0.020 |
Why?
|
Genotype | 1 | 2012 | 4249 | 0.010 |
Why?
|
Hydrolysis | 1 | 2004 | 233 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2012 | 5585 | 0.010 |
Why?
|
Osteoporosis | 1 | 2005 | 232 | 0.010 |
Why?
|
Age Distribution | 1 | 2005 | 713 | 0.010 |
Why?
|
Cause of Death | 1 | 2006 | 778 | 0.010 |
Why?
|
Reference Values | 1 | 2005 | 1130 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 8107 | 0.010 |
Why?
|
Fenretinide | 1 | 2002 | 100 | 0.010 |
Why?
|
Infant | 1 | 2018 | 13946 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 15900 | 0.010 |
Why?
|
Hysterectomy | 1 | 2005 | 651 | 0.010 |
Why?
|
Uterine Neoplasms | 1 | 2006 | 576 | 0.010 |
Why?
|
Child, Preschool | 1 | 2018 | 16987 | 0.010 |
Why?
|
Receptors, Retinoic Acid | 1 | 2002 | 369 | 0.010 |
Why?
|
Alleles | 1 | 2007 | 2590 | 0.010 |
Why?
|
Prodrugs | 1 | 2002 | 226 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 16640 | 0.010 |
Why?
|
Thrombosis | 1 | 2006 | 741 | 0.010 |
Why?
|
Cohort Studies | 1 | 2012 | 9464 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2008 | 5099 | 0.010 |
Why?
|
Comorbidity | 1 | 2005 | 2389 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2008 | 5309 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 4318 | 0.010 |
Why?
|
Stroke | 1 | 2005 | 1057 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 32647 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2002 | 1957 | 0.010 |
Why?
|
Disease Progression | 1 | 2008 | 6840 | 0.010 |
Why?
|
Child | 1 | 2018 | 30466 | 0.010 |
Why?
|
Signal Transduction | 1 | 2014 | 12087 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2007 | 4646 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2005 | 4360 | 0.010 |
Why?
|
Survival Analysis | 1 | 2005 | 9288 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2002 | 3343 | 0.010 |
Why?
|
Animals | 1 | 2004 | 61714 | 0.000 |
Why?
|